Journal of Neuro-Oncology

, Volume 102, Issue 3, pp 443–449 | Cite as

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy

  • Yasuo Iwadate
  • Tomoo Matsutani
  • Yuzo Hasegawa
  • Natsuki Shinozaki
  • Yoshinori Higuchi
  • Naokatsu Saeki
Clinical Study – Patient Study


Despite the accumulating evidences of high chemosensitivity especially in anaplastic oligodendrogliomas with loss of chromosomes 1p and 19q, the optimal management strategy for low-grade tumors using the 1p/19q information remains controversial. We have treated all low-grade oligodendrogliomas by a chemotherapy-preceding strategy without radiotherapy, and here we analyzed the survival outcomes of 36 consecutive patients in relation to 1p/19q status. The treatment protocol was as follows: (1) simple observation after gross total resection, and (2) modified PCV chemotherapy for postoperative residual tumors or recurrence after total resection. The 1p and 19q status were analyzed by fluorescence in situ hybridization. The median follow-up period was 7.5 years and no patient was lost during the follow-up periods. 1p/19q co-deletion was observed in 72% of the patients, and there was no significant association between 1p/19q co-deletion and chemotherapy response rate. The 5- and 10-year progression-free survival (PFS) rate was 75.1 and 46.9%, respectively, and the median PFS was 121 months for 1p/19q-deleted tumors and 101 months for non-deleted tumors (log-rank test: P = 0.894). Extent of surgery did not affect PFS (P = 0.685). In contrast, the elder patients (>50) had significantly shorter PFS (P = 0.0458). Recurrent tumors were well controlled by chemotherapy irrespective of 1p/19q status, and 35 out of 36 patients survived without receiving radiotherapy. The 5- and 10-year overall survival rates were 100 and 93.8%, respectively. Two of the patients in their sixties (29%) suffered from severe cognitive dysfunctions and marked brain atrophy following chemotherapy alone. These results show that low-grade oligodendrogliomas could be successfully treated by surgical resection and nitrosourea-based chemotherapy alone without radiotherapy irrespective of 1p/19q status.


1p/19q Chemotherapy Leukoencephalopathy Neurotoxicity Oligodendroglial tumor PCV 


Conflict of interest

There are no financial disclosures from the authors.


  1. 1.
    Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van Glabbeke M (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade gliomas in the adult: European Organization for Research and Treatment of Cancer Study 22845 with Medical Research Council Study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316–324PubMedCrossRefGoogle Scholar
  2. 2.
    Shaw E, Arusell R, Scheithauer B et al (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Group study. J Clin Oncol 20:2267–2276PubMedCrossRefGoogle Scholar
  3. 3.
    van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990PubMedCrossRefGoogle Scholar
  4. 4.
    Papagikos MA, Shaw EG, Stieber VW (2005) Lessons from randomized clinical trials in adult low grade glioma. Lancet Oncol 6:240–244PubMedCrossRefGoogle Scholar
  5. 5.
    Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y (2003) Primary brain tumors in adults. Lancet 361:323–331PubMedCrossRefGoogle Scholar
  6. 6.
    Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2:395–403PubMedCrossRefGoogle Scholar
  7. 7.
    Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57:172–175PubMedCrossRefGoogle Scholar
  8. 8.
    Caincross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714CrossRefGoogle Scholar
  9. 9.
    van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRefGoogle Scholar
  10. 10.
    Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133–3138PubMedCrossRefGoogle Scholar
  11. 11.
    Kanner AA, Staugaitis SM, Castilla EA et al (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104:542–550PubMedCrossRefGoogle Scholar
  12. 12.
    Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger M, Reinert MM (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758–4763PubMedCrossRefGoogle Scholar
  13. 13.
    Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC (2006) Current strategies in treatment of oligodendroglioma: evolution of molecular signature of response. J Clin Oncol 24:1246–1252PubMedCrossRefGoogle Scholar
  14. 14.
    Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937PubMedCrossRefGoogle Scholar
  15. 15.
    Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360–369PubMedCrossRefGoogle Scholar
  16. 16.
    Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas. Predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831–1836PubMedCrossRefGoogle Scholar
  17. 17.
    Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G (2009) Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 53:305–309PubMedCrossRefGoogle Scholar
  18. 18.
    Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendrogliomas respond to chemotherapy. Neurology 46:203–207PubMedGoogle Scholar
  19. 19.
    Higuchi Y, Iwadate Y, Yamaura A (2004) Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 63:2384–2386PubMedGoogle Scholar
  20. 20.
    Sunyach MP, Jouvet A, Perol D, Jouanneau E, Guyotat J, Gignoux L, Carrie C, Frappaz D (2007) Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol 85:319–328PubMedCrossRefGoogle Scholar
  21. 21.
    Bromberg JEC, van den Bent MJ (2009) Oligodendrogliomas: molecular biology and treatment. Oncologist 14:155–163PubMedCrossRefGoogle Scholar
  22. 22.
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  23. 23.
    Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861PubMedCrossRefGoogle Scholar
  24. 24.
    Shaw EG, Scheithauser BW, O’Fallon JR, Tazellar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434PubMedCrossRefGoogle Scholar
  25. 25.
    Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018–1034PubMedCrossRefGoogle Scholar
  26. 26.
    Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301PubMedGoogle Scholar
  27. 27.
    Leonardi MA, Lumenta CB (2001) Oligodendrogliomas in CT/MR-era. Acta Neurochir 143:1195–1203CrossRefGoogle Scholar
  28. 28.
    Okamoto Y, Di Patre OL, Birkhard C et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56PubMedCrossRefGoogle Scholar
  29. 29.
    Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels JF, Bourg V, Paquis P, Chatel M, Frenay M, Nice Brain Tumor Study Group (2004) Long-term outcome of oligodendrogliomas. Neurology 62:1783–1787PubMedGoogle Scholar
  30. 30.
    Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY (2002) Treatment outcome and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54:1405–1409PubMedCrossRefGoogle Scholar
  31. 31.
    Kang H-C, Kim IH, Eom K-Y, Kim JH, Jung H-W (2009) The role of radiotherapy in the treatment of newly diagnosed supratentorial low-grade oligodendrogliomas: comparative analysis with immediate radiotherapy versus surgery alone. Cancer Res Treat 41:132–137PubMedCrossRefGoogle Scholar
  32. 32.
    Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448PubMedGoogle Scholar
  33. 33.
    Ozyigit G, Onal C, Gurkaynak M, Soylemezoklu F, Zorlu F (2005) Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neurooncol 75:189–193PubMedCrossRefGoogle Scholar
  34. 34.
    El-Hatter H, Souhami L, Roberge D, Del Maestro R, Leblanc R, Eldebawy E, Muanza T, Melancon D, Kavan P, Guiot MC (2009) Low-grade oligodendroglioma: an indolent but incurable disease? J Neurosurg 111:265–271CrossRefGoogle Scholar
  35. 35.
    Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103:802–809PubMedCrossRefGoogle Scholar
  36. 36.
    Ty AU, See SJ, Rao JP, Khoo JB, Wong MC (2006) Oligodendroglial tumor chemotherapy using “decreased-dose-intensity” PCV: a Singapore experience. Neurology 66:247–249PubMedCrossRefGoogle Scholar
  37. 37.
    Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391–398PubMedCrossRefGoogle Scholar
  38. 38.
    Buckner JC, Geame D, O’Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low grade oligodendroglioma and oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255PubMedCrossRefGoogle Scholar
  39. 39.
    Postma TJ, van Groeningen CJ, Witjes RJ, Weerts JG, Kralendonk JH, Heimans JJ (1998) Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38:69–75PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Yasuo Iwadate
    • 1
  • Tomoo Matsutani
    • 1
  • Yuzo Hasegawa
    • 1
  • Natsuki Shinozaki
    • 1
  • Yoshinori Higuchi
    • 1
  • Naokatsu Saeki
    • 1
  1. 1.Department of Neurological SurgeryChiba University Graduate School of MedicineChibaJapan

Personalised recommendations